All systems operational
Q2 2024

Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B

Khalid Alswat · Riham Soliman · Nabiel N. H. Mikhail · Necati Örmeci · George N. Dalekos · Moutaz F. M. Derbala · Said Ahmed Al-Busafi · Waseem Hamoudi · Gamal Shiha
10.4103/sjg.sjg_27_24 391 Views 6 Citations
6
Citations
391
Views
Abstract


Background:
We recently developed a simple novel index called fibrosis 6 (FIB-6) using machine learning data analysis. We aimed to evaluate its performance in the diagnosis of liver fibrosis and cirrhosis in chronic hepatitis B (CHB).


Methods:
A retrospective observational analysis of data was obtained from seven countries (Egypt, Kingdom of Saudi Arabia (KSA), Turkey, Greece, Oman, Qatar, and Jordan) of CHB patients. The inclusion criteria were receiving an adequate liver biopsy and a complete biochemical and hematological data. The diagnostic performance analysis of the FIB-6 index was conducted and compared with other non-invasive scores.


Results:
A total of 603 patients were included for the analysis; the area under the receiver operating characteristic curve (AUROC) of FIB-6 for the discrimination of patients with cirrhosis (F4), compensated advanced chronic liver disease (cACLD) (F3 and F4), and significant fibrosis (F2–F4) was 0.854, 0.812, and 0.745, respectively. The analysis using the optimal cut-offs of FIB-6 showed a sensitivity of 70.9%, specificity of 84.1%, positive predictive value (PPV) of 40.3%, and negative predictive value (NPV) of 95.0% for the diagnosis of cirrhosis. For the diagnosis of cACLD, the results were 71.5%, 69.3%, 40.8%, and 89.2%, respectively, while for the diagnosis of significant fibrosis, the results were 68.3%, 67.5%, 59.9%, and 75.0%, respectively. When compared to those of fibrosis 4 (FIB-4) index, aspartate aminotransferase (AST)-to-platelet ratio index (APRI), and AST-to-alanine aminotransferase (ALT) ratio (AAR), the AUROC for the performance of FIB-6 was higher than that of FIB-4, APRI, and AAR in all fibrosis stages. FIB-6 gave the highest sensitivity and NPV (89.1% and 92.4%) in ruling out cACLD and cirrhosis, as compared to FIB-4 (63.8% and 83.0%), APRI (53.9% and 86.6%), and AAR (47.5% and 82.3%), respectively.


Conclusions:
The FIB-6 index could be used in ruling out cACLD, fibrosis, and cirrhosis with good reliability.

Cite this Article (APA)
Khalid, A., Riham, S., Nabiel, N. H. M., Necati, Ö., George, N. D., Moutaz, F. M. D., Said, A. A., Waseem, H., Gamal, S. (2024). Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B. Saudi Journal of Gastroenterology. https://doi.org/10.4103/sjg.sjg_27_24
Related Papers
The burden of metabolic dysfunction-associated steatotic liver disease and viral hepatitis in Saudi …
Saleh A. Alqahtani; Faisal Abaalkhail; Saad Alghamdi; Khalid Bzeizi; Waleed K. A · 2024
20
cites
397
CEBPB dampens the cuproptosis sensitivity of colorectal cancer cells by facilitating the PI3K/AKT/mT…
Tianchen Huang; Yong Zhang; Yachao Wu; Xiaodong Han; Lei Li; Zhipeng Guo; Kan Li · 2024
15
cites
398
SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024
Abdullah S. Alghamdi; Hamdan Alghamdi; Haleema A. Alserehi; Mohammed A. Babatin; · 2024
11
cites
395
The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real w…
Nahla Azzam; Othman Alharbi; Mansour Altuwaijri; Yazed Alruthia; Heba Alfarhan; · 2024
9
cites
395
The Saudi Gastroenterology Association consensus on the clinical care pathway for the diagnosis and …
Mohammed A. Alzahrani; Abdullah M. Alqaraawi; Saeed R. Alzubide; Ehab Abufarhane · 2024
7
cites
395
Access
View Full Text via DOI
Published in
ISSN 1319-3767
Quartile Q2
AMS Score 93
Field Medicine & Health Sciences
Publisher Wolters Kluwer / Saudi Gastroentero
Country 🇸🇦 Saudi Arabia
View Journal Profile →
Authors
Publication Details
Year 2024
Language English
Added 23 Jul 2026